The use of specialized enteral formulas in pulmonary disease

The relationship between pulmonary disease and nutrition is significant. Malnutrition and its associated adverse pulmonary effects can directly affect outcomes in the individual with pulmonary disease. The use of nutrition support is common for these patients as a supportive or therapeutic measure. Historical reports of adverse respiratory function associated with high parenteral carbohydrate intakes have led to the controversial use of high-fat enteral products in patients with chronic pulmonary dysfunction. The rationale for using this type of formula is that by providing less carbohydrates, carbon dioxide production will be reduced, respiratory quotient will therefore decrease, and a favorable respiratory outcome will result. In the patient with acute respiratory distress syndrome, an inflammatory state exists in which proinflammatory mediators are produced and affect the course of the disease. An enteral formula with modified lipids designed to modulate eicosanoid production and therefore influence the inflammatory cascade is available. This article reviews the rationale for use of modified enteral formulas in both chronic and acute pulmonary disease, reviews the available studies evaluating the efficacy of these formulas, and provides overall recommendations for the use of specialized enteral formulas in individuals with pulmonary disease.